Abstract: The object of the present invention is to provide a Ras/Raf binding inhibitory compound exhibiting a Ras/Raf signaling inhibitory action even against cancer cells bearing proved drug resistance and those with a variety of Ras mutations. The Ras/Raf binding inhibitory compound of the present invention is represented by the following formula (I) (wherein A, B, X, and R1 to R4 are as defined in the present description).

Abstract: This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: wherein Ar1 and Ar2 each represent aryl or heteroaryl; L represents O, S, NH, NHCO, or CONH; X represents CH or N; Y represents C1-3-alkylene; Z1 represents hydrogen, C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl; and Z2 represents C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl, Z1 and Z2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to Z1 and Z2.

Abstract: An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6 alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; R4 represents hydrogen atom, a C1-6 alkyl group, a C1-6 alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6 alkyl group and the like; R8 represents hydrogen atom, a C1-6 alkyl group and the like; A represents —O—, —S—, or —CH2—; D represents —C? or —N?; X represents methylene group, —O—, or —CO—; Q represents —N? or —C(R8)?; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.

Abstract: This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: wherein Ar1 and Ar2 each represent aryl or heteroaryl; L represents O, S, NH, NHCO, or CONH; X represents CH or N; Y represents C1-3-alkylene; Z1 represents hydrogen, C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl; and Z2 represents C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl, Z1 and Z2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to Z1 and Z2.

Abstract: An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6 alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; R4 represents hydrogen atom, a C1-6 alkyl group, a C1-6 alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6 alkyl group and the like; R8 represents hydrogen atom, a C1-6 alkyl group and the like; A represents —O—, —S—, or —CH2—; D represents —C? or —N?; X represents methylene group, —O—, or —CO—; Q represents —N? or —C(R8)?; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.